AZD-5069

Name: AZD-5069
Brand: MedChemExpress
SKU: HY-19855
Rating: 5.0 (11 reviews)

Cat. No.: HY-19855 Purity: 99.91%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

For research use only. We do not sell to patients.

CAS No. : 878385-84-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

11 Publications Citing Use of MCE AZD-5069

In Vivo Efficacy Study

Histological Imaging/Staining

RT-PCR

: AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]; Quantification of infarct volume and endogenous IgG positive area of mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 and vehicle 7 days after MCAO (n = 6 per group, one-way ANOVA with Bonferroni multiple comparisons test).

: AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]; Representative MAP2 staining of brain infarct and endogenous mouse IgG staining of BBB leakage 7 days after MCAO in mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 or vehicle via ICV injection.

: AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]; Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.

: AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]; Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.

: AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]; AZD5069 treatment lowered viral loads in brains of S41-infected mice from 4 to 7 dpi.

: AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]; pERK1/2 and ERK1/2 levels were reduced in AZD5069-treated mice.

: AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]; Brain lysates of S41- or UI-infected mice with or without AZD5069 treatment were subjected to immunoblotting analyses at 7 dpi. AZD5069 treatment delays the expression of HEVA71 viral proteins. Immunoblot representative of 3 biological repeats is shown.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

IC₅₀ & Target^[1]

¹²⁵I-IL-8-CXCR2

In Vitro

AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [¹²⁵I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca²⁺ flux in human neutrophils loaded with fluo-3 dye^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

476.52

Formula

C₁₈H₂₂F₂N₄O₅S₂

CAS No.

878385-84-3

Appearance

Solid

Color

White to light yellow

SMILES

O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 90 mg/mL (188.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0985 mL	10.4927 mL	20.9855 mL
5 mM	0.4197 mL	2.0985 mL	4.1971 mL
10 mM	0.2099 mL	1.0493 mL	2.0985 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.62 mg/mL (5.50 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (276 KB) SDS (643 KB)

COA (252 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Norman P, et al. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0985 mL	10.4927 mL	20.9855 mL	52.4637 mL
	5 mM	0.4197 mL	2.0985 mL	4.1971 mL	10.4927 mL
	10 mM	0.2099 mL	1.0493 mL	2.0985 mL	5.2464 mL
	15 mM	0.1399 mL	0.6995 mL	1.3990 mL	3.4976 mL
	20 mM	0.1049 mL	0.5246 mL	1.0493 mL	2.6232 mL
	25 mM	0.0839 mL	0.4197 mL	0.8394 mL	2.0985 mL
	30 mM	0.0700 mL	0.3498 mL	0.6995 mL	1.7488 mL
	40 mM	0.0525 mL	0.2623 mL	0.5246 mL	1.3116 mL
	50 mM	0.0420 mL	0.2099 mL	0.4197 mL	1.0493 mL
	60 mM	0.0350 mL	0.1749 mL	0.3498 mL	0.8744 mL
	80 mM	0.0262 mL	0.1312 mL	0.2623 mL	0.6558 mL
	100 mM	0.0210 mL	0.1049 mL	0.2099 mL	0.5246 mL

AZD-5069 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD-5069878385-84-3AZD5069AZD 5069CXCRCXC chemokine receptorsC-X-C motif chemokine receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

AZD-5069

Customer Review

AZD-5069 Related Antibodies

11 Publications Citing Use of MCE AZD-5069

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

AZD-5069 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD-5069 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report